Search Results - Therapeutics

45 Results Sort By:
Novel Oncolytic Herpes Simplex Virus (oHSV) for Cancer Treatment
­ Researchers from UTHealth have developed a novel oncolytic viral therapy, oHSV-shPKR, which can inhibit tumor cells’ antiviral PKR activity, and increase oncolytic virus infection and replication in both oncolytic viral-resistant and sensitive cancer cells. This novel oHSV-shPKR therapy can significantly increase the anti-tumor immune response...
Published: 1/7/2022   |   Inventor(s):  
Category(s): Biologics, Oncology, Therapeutics
Co-Administration of Oncolytic Herpes Simplex Virus (oHSV) with Cisplatin for Anti-Cancer Immunotherapy
­Researchers from UTHealth and Ohio State University College of Medicine have collaborated to investigate the impact of oHSV therapy in combination with platinum agents using platinum-resistant high-grade serous ovarian carcinoma (HGSOC) as well as platinum-resistant ovarian clear cell carcinoma models. More importantly, they have developed a novel...
Published: 1/7/2022   |   Inventor(s):  
Category(s): Therapeutics, Oncology
Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use
­Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal a role for OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...
Published: 12/16/2021   |   Inventor(s):  
Category(s): Diagnostics, Therapeutics, Biologics, Oncology
Peptides Targeting Chemotherapy-Resistant Metastatic Cancer Cells for Therapeutic and Diagnostic Use
Researchers at UTHealth have identified new molecules that selectively target metastatic cancer cells in mammals both in vitro and in vivo by screening a combinatorial library in a mouse mammary tumor model of spontaneous metastasis, and demonstrated their application as noninvasive imaging probes and vehicles for cytotoxic therapy delivery in preclinical...
Published: 12/16/2021   |   Inventor(s):  
Category(s): Oncology, Therapeutics, Diagnostics
Monoclonal Antibodies Against Chitinase 3-like-1 (Chi3l1) for Therapeutic and Diagnostic Use
­Researchers at UTHealth have unveiled a critical role of Chi3l1 in hepatic platelet recruitment during acetaminophen (APAP)-induced liver injury (AILI) using murine models of AILI and concanavalin A (Con A)-induced hepatitis. Significantly, they have developed anti-Chi3l1 monoclonal antibodies and demonstrated the feasibility of targeting CHI3L1...
Published: 12/6/2021   |   Inventor(s): Zhiqiang An, Changqing (Cynthia) Ju
Category(s): Biologics, Therapeutics, Oncology
Novel Channelrhodopsins for Optogenetics Gene Therapy
Novel Channelrhodopsins for Optogenetics Gene Therapy When expressed in targeted neurons, light-sensitive channelrhodopsin proteins (ChRs) have the ability to selectively manipulate neuronal activity in a light-dependent manner. Gene therapy using anion ChRs (ACRs) has the potential for treating excessive neuron firing in conditions such as Parkinson’s...
Published: 6/2/2021   |   Inventor(s): John Spudich, Elena G Govorunova, Oleg A Sineshchekov
Category(s): Therapeutics, Research Materials
Novel Fendiline Derivatives for the Treatment of KRAS Mutant Tumors
Novel Compounds and Methods of Use for the Treatment and Prevention of Cancer via Inhibition of the K-Ras Pathway Background: The Ras protein family members belong to a class of proteins called small GTPases and when activated by incoming signals, it subsequently switches on other genes involved in cell growth, differentiation, and survival. As a...
Published: 9/22/2020   |   Inventor(s):  
Category(s): Oncology, Therapeutics
Method of Attenuation and Repair of Brain Lesions in Multiple Sclerosis Patients
BackgroundACZ is a reversible carbonic anhydrase enzyme inhibitor. This now generic medication has a good safety and tolerability profile, and is known to transiently enhance cerebral perfusion. Enhancing perfusion might improve tissue integrity within areas previously injured. Technology Overview- Patients tolerated doses of ACZ up to 4000 mg daily...
Published: 8/4/2020   |   Inventor(s): Jerry Wolinsky, John A Lincoln, Ponnada Narayana
Category(s): Therapeutics
Repurposing FDA-approved Drug Nilotinib for Cancer Cachexia Treatment
Nilotinib (TasignaTM) is an off-patent, FDA-approved kinase inhibitor. Researchers at UTHealth have discovered it as a promising repurposed drug for muscle wasting treatment at a significantly lower than FDA-approved dose. At 500 nM in vitro, it abrogates muscle catabolism without suppressing myogenesis by selectively inhibiting p38β MAPK, and...
Published: 4/15/2020   |   Inventor(s):  
Category(s): Therapeutics
Monoclonal antibodies against human and mouse leptin for therapeutic and diagonostic use.
BackgroundLeptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was...
Published: 3/5/2020   |   Inventor(s): Zhiqiang An, Philipp Scherer, Ningyan Zhang
Category(s): Biologics, Oncology, Therapeutics, Metabolism
1 2 3 4 5 
© 2022. All Rights Reserved. Powered by Inteum